Ultrasound Guided Interscalene, Suprascapular and Anterior Glenoid Nerve Blocks on Diaphragmatic Excursion and Analgesia Following Arthroscopic Shoulder Surgery

NCT ID: NCT07090733

Last Updated: 2025-07-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-01
• Study Completion Date: 2025-12-31

Brief Summary

This study aims to evaluate the diaphragmatic movement and postoperative analgesia following anterior glenoid, suprascapular, and interscalene nerve blocks in patients undergoing elective arthroscopic shoulder surgery.

Detailed Description

Arthroscopic shoulder surgery is a key approach for diagnosing and treating many shoulder disorders. Nevertheless, 30-70% of patients often experience moderate to severe pain, especially at 48 h after the operation, which affects rapid recovery.

The interscalene brachial plexus block (ISB) remains the gold standard for providing analgesia after shoulder surgery. Suprascapular nerve block (SSNB) is the most commonly used regional nerve block. Seventy percent of the sensory nerve fibers of the shoulder joint are innervated by the suprascapular nerve (SSN), with the supraspinatus and infraspinatus being directly innervated by the SSN.

Conditions

Interscalene Block; Suprascapular Nerve Block; Anterior Glenoid Nerve Block; Diaphragmatic Excursion; Analgesia; Arthroscopic Shoulder Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Group I

Patients will receive general anesthesia, plus an ultrasound-guided Interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB)

Group Type: ACTIVE_COMPARATOR

Interscalene brachial plexus block

Intervention Type: OTHER

Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.

Group II

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Group Type: EXPERIMENTAL

Suprascapular nerve block

Intervention Type: OTHER

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Group III

Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Group Type: EXPERIMENTAL

Anterior glenoid block

Intervention Type: OTHER

Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Group IV

Patients will receive general anesthesia, along with a total volume of 30 mL of bupivacaine 0.25%, divided into 15 mL of Bupivacaine 0.25% for ultrasound-guided SSNB and 15 mL of Bupivacaine 0.25% for ultrasound-guided anterior glenoid block.

Group Type: EXPERIMENTAL

Suprascapular nerve block + Anterior glenoid block

Intervention Type: OTHER

Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.

Interventions

Interscalene brachial plexus block

Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.

Intervention Type: OTHER

Suprascapular nerve block

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Intervention Type: OTHER

Anterior glenoid block

Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Intervention Type: OTHER

Suprascapular nerve block + Anterior glenoid block

Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.

Intervention Type: OTHER

Other Intervention Names

15 ml of 0.25% bupivacaine; 15 ml of 0.25% bupivacaine; 15 ml of 0.25% bupivacaine; 30 mL of 0.25% bupivacaine

Eligibility Criteria

Inclusion Criteria

• Age from 21 to 65 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status I or II.
• Scheduled for arthroscopic shoulder surgery.

Exclusion Criteria

• Patient's refusal to participate.
• Patients with a history of allergy to local anesthetics.
• Patients with a history of chronic use of painkillers.
• Patients presented with mental dysfunction.
• Patients with coagulation disorders.
• Patients presented with skin or soft tissue infection at the proposed site of needle Insertion.
• Pregnant Patients.
• Patients with Chronic Obstructive Pulmonary Disease (COPD) or a Body Mass Index (BMI) of more than 40.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tanta University

OTHER

Sponsor Role: lead

Responsible Party

Fatma Elsamahy

Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Tanta University

Tanta, El-Gharbia, Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Fatma E Elsamahy, Master

Role: CONTACT

Drfatmaelsamahy@gmail.com

00201094082899

Facility Contacts

Fatma E Elsamahy, Master

Role: primary

Drfatmaelsamahy@gmail.com

00201094082899

Other Identifiers

36265MD/12/24

Identifier Type: -

Identifier Source: org_study_id